ArticleBMC gastroenterology2025
Confirmation of Helicobacter pylori eradication using ¹³C urea breath test: addressing the regional post-treatment outcomes.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Simultaneous point-of-care detection and virulence typing of Helicobacter pylori using multiplex recombinase polymerase amplification combined with lateral flow strip.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a major etiological factor of the gastrointestinal diseases, the presence of Helicobacter pylori (H. pylori) poses a serious concern to the clinical management; however, the confirmation of the eradication post-therapy is of utmost crucial. The purpose of this study was to use the 13C Urea Breath Test (UBT) in measuring the effectiveness of second-line quadruple therapy in assessing treatment failure due to the infection with resistant strains of H. pylori, particularly in the state of Odisha.
methodsThe study included 70 adult patients (mean age 42.5 ± 12.7 years) with H. pylori infection who participated in first-line eradication therapy. The 13C UBT was performed approximately 50.4 ± 14.4 days after therapy to determine the eradication success. Patients who have tested positive in the initial treatment were subjected to second-line quadruple therapy. The collected data in a designed proforma and excel sheet were analyzed using statistical software SPSS version 21. Descriptive statistics summarized demographic and clinical variables.
resultsAmong the study participants, 75.75% had negative H. pylori in UBT, indicating successful eradication, and 24.29% were still positive and received second-line quadruple therapy. In situations where H. pylori was not eradicated, the likelihood of geographic fatal H. pylori strains that were also not eradicated using conventional methods was established. In more than two-thirds of the patients, an improvement in their symptoms was observed, and among their common complaints were bloating (61%) and heartburn (40%). A subset of the patients had comorbidities, such as diabetes and metabolic-associated steatohepatitis (MASLD), which were also noted.
conclusionThe 13C UBT is crucial and non-invasive test and is used to verify whether H. pylori has been eradicated after treatment. Since the efficacy of UBT has already been proven, it plays a significantly important role in cases of treatment failure, especially in regions resistant to strains. Regional variations in strain identification should be studied for more efficient treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.